{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:28:04Z","timestamp":1793276884990,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T00:00:00Z","timestamp":1518566400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Finalizzata, 10\/PE-2011-02350147"],"award-info":[{"award-number":["Ricerca Finalizzata, 10\/PE-2011-02350147"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004710","name":"Fondazione Umberto Veronesi","doi-asserted-by":"publisher","award":["n.a."],"award-info":[{"award-number":["n.a."]}],"id":[{"id":"10.13039\/501100004710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00277-018-3276-y","type":"journal-article","created":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T23:16:01Z","timestamp":1518563761000},"page":"1009-1018","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy"],"prefix":"10.1007","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-4433","authenticated-orcid":false,"given":"Alessandra","family":"Romano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunziatina Laura","family":"Parrinello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogero","family":"Vetro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Chiarenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Cerchione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Ippolito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Alberto","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,14]]},"reference":[{"key":"3276_CR1","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/bjh.13198","volume":"168","author":"A Romano","year":"2015","unstructured":"Romano A, Parrinello NL, Vetro C, Forte S, Chiarenza A, Figuera A, Motta G, Palumbo GA, Ippolito M, Consoli U, Raimondo FD (2015) Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin lymphoma patients treated up-front with a risk-adapted strategy. Br J Haematol 168:689\u2013700","journal-title":"Br J Haematol"},{"key":"3276_CR2","doi-asserted-by":"crossref","first-page":"67333","DOI":"10.18632\/oncotarget.12024","volume":"7","author":"A Romano","year":"2016","unstructured":"Romano A, Parrinello NL, Vetro C, Tibullo D, Giallongo C, la Cava P, Chiarenza A, Motta G, Caruso AL, Villari L, Tripodo C, Cosentino S, Ippolito M, Consoli U, Gallamini A, Pileri S, di Raimondo F (2016) The prognostic value of the myeloid-mediated immunosuppression marker arginase-1 in classic Hodgkin lymphoma. Oncotarget 7:67333\u201367346","journal-title":"Oncotarget"},{"key":"3276_CR3","doi-asserted-by":"publisher","first-page":"e2014039","DOI":"10.4084\/mjhid.2014.039","volume":"6","author":"A Romano","year":"2014","unstructured":"Romano A, Vetro C, Caocci G et al (2014) Immunological deregulation in classic Hodgkin lymphoma. Mediterr J Hematol Infect Dis 6:e2014039","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"3276_CR4","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3324\/haematol.2012.063909","volume":"97","author":"A Gallamini","year":"2012","unstructured":"Gallamini A, Kostakoglu L (2012) Positron emission tomography\/computed tomography surveillance in patients with lymphoma: a fox hunt? Haematologica 97:797\u2013799","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"3276_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/annonc\/13.S1.75","volume":"13","author":"D Hasenclever","year":"2002","unstructured":"Hasenclever D (2002) The disappearance of prognostic factors in Hodgkin\u2019s disease. Ann Oncol 13(Suppl 1):75\u201378","journal-title":"Ann Oncol"},{"key":"3276_CR6","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","volume":"339","author":"D Hasenclever","year":"1998","unstructured":"Hasenclever D, Diehl VA (1998) Prognostic score for advanced Hodgkin\u2019s disease. International prognostic factors project on advanced Hodgkin\u2019s disease. N Engl J Med 339:1506\u20131514","journal-title":"N Engl J Med"},{"key":"3276_CR7","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","volume":"25","author":"A Gallamini","year":"2007","unstructured":"Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, di Raimondo F, D'Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin\u2019s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25:3746\u20133752","journal-title":"J Clin Oncol"},{"key":"3276_CR8","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.3324\/haematol.2012.064576","volume":"97","author":"A Romano","year":"2012","unstructured":"Romano A, Vetro C, Donnarumma D, Forte S, Ippolito M, di Raimondo F (2012) Early interim 2-(1)fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to peripheral blood lymphocyte\/monocyte ratio at diagnosis in classical Hodgkin\u2019s lymphoma. Haematologica 97:e21\u2013e23 author reply e24","journal-title":"Haematologica"},{"key":"3276_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.imlet.2013.09.011","volume":"155","author":"A Gallamini","year":"2013","unstructured":"Gallamini A, Di Raimondo F, La Nasa G et al (2013) Standard therapies versus novel therapies in Hodgkin lymphoma. Immunol Lett 155:56\u201359","journal-title":"Immunol Lett"},{"key":"3276_CR10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/bjh.12715","volume":"165","author":"Y Oki","year":"2014","unstructured":"Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A (2014) The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 165:112\u2013116","journal-title":"Br J Haematol"},{"key":"3276_CR11","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1182\/blood-2012-03-403790","volume":"120","author":"A Gallamini","year":"2012","unstructured":"Gallamini A, Kostakoglu L (2012) Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials? Blood 120:4913\u20134920","journal-title":"Blood"},{"key":"3276_CR12","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/j.1365-2141.2010.08485.x","volume":"152","author":"A Gallamini","year":"2011","unstructured":"Gallamini A, Patti C, Viviani S, Rossi A, Fiore F, di Raimondo F, Cantonetti M, Stelitano C, Feldman T, Gavarotti P, Sorasio R, Mul\u00e8 A, Leone M, Rambaldi A, Biggi A, Barrington S, Fallanca F, Ficola U, Chauvie S, Gianni AM, for the Gruppo Italiano Terapie Innovative nei Linfomi (GITIL) (2011) Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with an interim-PET positive after two ABVD courses. Br J Haematol 152:551\u2013560","journal-title":"Br J Haematol"},{"key":"3276_CR13","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1200\/JCO.2015.63.0699","volume":"34","author":"PL Zinzani","year":"2016","unstructured":"Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, Santoro A, Ricardi U, Bonfichi M, Brusamolino E, Rossi G, Anastasia A, Zaja F, Vitolo U, Pavone V, Pulsoni A, Rigacci L, Gaidano G, Stelitano C, Salvi F, Rusconi C, Tani M, Freilone R, Pregno P, Borsatti E, Sacchetti GM, Argnani L, Levis A (2016) Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study. J Clin Oncol 34:1376\u20131385","journal-title":"J Clin Oncol"},{"key":"3276_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s12307-011-0091-6","volume":"5","author":"A Sica","year":"2012","unstructured":"Sica A, Porta C, Morlacchi S, Banfi S, Strauss L, Rimoldi M, Totaro MG, Riboldi E (2012) Origin and functions of tumor-associated myeloid cells (TAMCs). Cancer Microenviron 5:133\u2013149","journal-title":"Cancer Microenviron"},{"key":"3276_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cytogfr.2017.05.002","volume":"35","author":"A Sica","year":"2017","unstructured":"Sica A, Strauss L, Consonni FM, Travelli C, Genazzani A, Porta C (2017) Metabolic regulation of suppressive myeloid cells in cancer. Cytokine Growth Factor Rev 35:27\u201335","journal-title":"Cytokine Growth Factor Rev"},{"key":"3276_CR16","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa0905680","volume":"362","author":"C Steidl","year":"2010","unstructured":"Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD (2010) Tumor-associated macrophages and survival in classic Hodgkin\u2019s lymphoma. N Engl J Med 362:875\u2013885","journal-title":"N Engl J Med"},{"key":"3276_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/hon.878","volume":"27","author":"S Schreck","year":"2009","unstructured":"Schreck S, Friebel D, Buettner M, Distel L, Grabenbauer G, Young LS, Niedobitek G (2009) Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol 27:31\u201339","journal-title":"Hematol Oncol"},{"key":"3276_CR18","doi-asserted-by":"publisher","first-page":"e467","DOI":"10.1016\/S2352-3026(16)30108-9","volume":"3","author":"C Agostinelli","year":"2016","unstructured":"Agostinelli C, Gallamini A, Stracqualursi L et al (2016) The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. Lancet Haematol 3:e467\u2013e479","journal-title":"Lancet Haematol"},{"key":"3276_CR19","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3324\/haematol.2011.050138","volume":"97","author":"LF Porrata","year":"2012","unstructured":"Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C, Markovic SN (2012) Peripheral blood lymphocyte\/monocyte ratio at diagnosis and survival in classical Hodgkin\u2019s lymphoma. Haematologica 97:262\u2013269","journal-title":"Haematologica"},{"key":"3276_CR20","doi-asserted-by":"publisher","unstructured":"Kelkitli E, Atay H, Cilingir F et al (2014) Predicting survival for multiple myeloma patients using baseline neutrophil\/lymphocyte ratio. Ann Hematol 93(5):841\u2013846. https:\/\/doi.org\/10.1007\/s00277-013-1978-8","DOI":"10.1007\/s00277-013-1978-8"},{"key":"3276_CR21","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1309\/AJCPO46GFKGNXCBR","volume":"138","author":"YW Koh","year":"2012","unstructured":"Koh YW, Kang HJ, Park C, Yoon DH, Kim S, Suh C, Kim JE, Kim CW, Huh J (2012) Prognostic significance of the ratio of absolute neutrophil count to absolute lymphocyte count in classic Hodgkin lymphoma. Am J Clin Pathol 138:846\u2013854","journal-title":"Am J Clin Pathol"},{"key":"3276_CR22","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/ajh.21849","volume":"85","author":"LF Porrata","year":"2010","unstructured":"Porrata LF, Ristow K, Habermann T, Inwards DJ, Micallef IN, Markovic SN (2010) Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil\/lymphocyte ratio. Am J Hematol 85:896\u2013899","journal-title":"Am J Hematol"},{"key":"3276_CR23","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1038\/bcj.2013.8","volume":"3","author":"LF Porrata","year":"2013","unstructured":"Porrata LF, Ristow KM, Habermann TM, Macon WR, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski G, Thompson CA, Markovic SN (2013) Peripheral blood absolute lymphocyte\/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma. Blood Cancer J 3:e110","journal-title":"Blood Cancer J"},{"key":"3276_CR24","first-page":"38","volume":"19","author":"V Bonfante","year":"1992","unstructured":"Bonfante V, Santoro A, Viviani S et al (1992) ABVD in the treatment of Hodgkin's disease. Semin Oncol 19:38\u201344 discussion 44-35","journal-title":"Semin Oncol"},{"key":"3276_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/BF00254081","volume":"2","author":"A Santoro","year":"1979","unstructured":"Santoro A, Bonadonna G (1979) Prolonged disease-free survival in MOPP-resistant Hodgkin\u2019s disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). Cancer Chemother Pharmacol 2:101\u2013105","journal-title":"Cancer Chemother Pharmacol"},{"key":"3276_CR26","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1007\/s00259-010-1490-5","volume":"37","author":"SF Barrington","year":"2010","unstructured":"Barrington SF, Qian W, Somer EJ, Franceschetto A, Bagni B, Brun E, Almquist H, Loft A, H\u00f8jgaard L, Federico M, Gallamini A, Smith P, Johnson P, Radford J, O\u2019Doherty MJ (2010) Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 37:1824\u20131833","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3276_CR27","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.3109\/10428194.2012.677535","volume":"53","author":"M Meignan","year":"2012","unstructured":"Meignan M, Gallamini A, Itti E, Barrington S, Haioun C, Polliack A (2012) Report on the Third International Workshop on interim positron emission. Leuk Lymphoma 53:1876\u20131881","journal-title":"Leuk Lymphoma"},{"key":"3276_CR28","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.3324\/haematol.2010.024885","volume":"95","author":"A Gallamini","year":"2010","unstructured":"Gallamini A (2010) Positron emission tomography scanning: a new paradigm for the management of Hodgkin\u2019s lymphoma. Haematologica 95:1046\u20131048","journal-title":"Haematologica"},{"key":"3276_CR29","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1634\/theoncologist.2012-0034","volume":"17","author":"YW Koh","year":"2012","unstructured":"Koh YW, Kang HJ, Park C, Yoon DH, Kim S, Suh C, Go H, Kim JE, Kim CW, Huh J (2012) The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin\u2019s lymphoma: correlation with tumor-associated macrophages. Oncologist 17:871\u2013880","journal-title":"Oncologist"},{"key":"3276_CR30","doi-asserted-by":"publisher","unstructured":"Marcheselli R, Bari A, Tadmor T et al (2016) Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients. Hematol Oncol 35(4):561\u2013566. https:\/\/doi.org\/10.1002\/hon.2359","DOI":"10.1002\/hon.2359"},{"key":"3276_CR31","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s10120-013-0330-2","volume":"17","author":"IR Cho","year":"2014","unstructured":"Cho IR, Park JC, Park CH, Jo JH, Lee HJ, Kim S, Shim CN, Lee H, Shin SK, Lee SK, Lee YC (2014) Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival outcomes in metastatic advanced gastric cancer. Gastric Cancer 17:703\u2013710","journal-title":"Gastric Cancer"},{"key":"3276_CR32","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/SLA.0b013e318297ad6b","volume":"258","author":"Y Mano","year":"2013","unstructured":"Mano Y, Shirabe K, Yamashita Y, Harimoto N, Tsujita E, Takeishi K, Aishima S, Ikegami T, Yoshizumi T, Yamanaka T, Maehara Y (2013) Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Ann Surg 258:301\u2013305","journal-title":"Ann Surg"},{"key":"3276_CR33","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s00277-015-2462-4","volume":"94","author":"A Romano","year":"2015","unstructured":"Romano A, Parrinello NL, Consoli ML, Marchionni L, Forte S, Conticello C, Pompa A, Corso A, Milone G, di Raimondo F, Borrello I (2015) Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents. Ann Hematol 94:1875\u20131883","journal-title":"Ann Hematol"},{"key":"3276_CR34","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1038\/bjc.2013.522","volume":"109","author":"M Santoni","year":"2013","unstructured":"Santoni M, De Giorgi U, Iacovelli R et al (2013) Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. Br J Cancer 109:1755\u20131759","journal-title":"Br J Cancer"},{"key":"3276_CR35","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","volume":"374","author":"P Johnson","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A, Foss\u00e5 A, Berkahn L, Carella A, d\u2019Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O\u2019Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S (2016) Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma. N Engl J Med 374:2419\u20132429","journal-title":"N Engl J Med"},{"key":"3276_CR36","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","volume":"34","author":"OW Press","year":"2016","unstructured":"Press OW, Li H, Schoder H et al (2016) US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816. J Clin Oncol 34:2020\u20132027","journal-title":"J Clin Oncol"},{"key":"3276_CR37","doi-asserted-by":"publisher","unstructured":"Reddy JP, Hernandez M, Gunther JR, Dabaja BS, Martin GV, Jiang W, Akhtari M, Allen PK, Atkinson BJ, Smith GL, Pinnix CC, Milgrom SA, Abou Yehia Z, Osborne EM, Oki Y, Lee H, Hagemeister F, Fanale MA (2018) Pre-treatment neutrophil\/lymphocyte ratio and platelet\/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma. Br J Haematol 180(4):545\u2013549. https:\/\/doi.org\/10.1111\/bjh.15054","DOI":"10.1111\/bjh.15054"},{"key":"3276_CR38","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2011.41.0910","volume":"30","author":"AA Moccia","year":"2012","unstructured":"Moccia AA, Donaldson J, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, Shenkier TN, Slack GW, Skinnider B, Gascoyne RD, Connors JM, Sehn LH (2012) International prognostic score in advanced-stage Hodgkin\u2019s lymphoma: altered utility in the modern era. J Clin Oncol 30:3383\u20133388","journal-title":"J Clin Oncol"},{"key":"3276_CR39","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/bjh.13634","volume":"171","author":"CS Diefenbach","year":"2015","unstructured":"Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, Crump M, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ, Advani RH (2015) Evaluation of the international prognostic score (IPS-7) and a simpler prognostic score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol 171:530\u2013538","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3276-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3276-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3276-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T03:53:42Z","timestamp":1603857222000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3276-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,14]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["3276"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3276-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,14]]},"assertion":[{"value":"19 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}